Opaleye Management’s UroGen Pharma URGN Stock Holding History

Opaleye Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$53M	Buy	1,439,996 +9,996	+0.7%	+$271K	4.8%	5
2026 Q1	$25.7M	Buy	1,430,000 +1,161,577	+433%	+$23.3M	3.39%	8
2025 Q4	$6.29M	Buy	+268,423	New	+$5.82M	0.83%	28
2025 Q1	–	Sell	-220,000	Closed	-$2.34M	–	54
2024 Q4	$2.34M	Sell	220,000 -184,100	-46%	-$2.2M	0.41%	30
2024 Q3	$5.13M	Sell	404,100 -7,900	-2%	-$117K	0.86%	24
2024 Q2	$6.91M	Buy	412,000 +142,000	+53%	+$2.02M	1.58%	21
2024 Q1	$4.05M	Sell	270,000 -50,000	-16%	-$817K	0.88%	30
2023 Q4	$4.8M	Hold	320,000	–	–	1.28%	22
2023 Q3	$4.48M	Sell	320,000 -250,000	-44%	-$4.01M	1.46%	19
2023 Q2	$5.9M	Buy	570,000 +65,000	+13%	+$717K	1.41%	19
2023 Q1	$4.67M	Buy	505,000 +16,344	+3%	+$150K	1.4%	25
2022 Q4	$4.33M	Buy	488,656 +91,156	+23%	+$863K	1.51%	21
2022 Q3	$3.31M	Buy	397,500 +158,830	+67%	+$1.31M	1.37%	20
2022 Q2	$1.96M	Buy	+238,670	New	+$1.64M	0.88%	28

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Opaleye Management's URGN Position: Q2 2026 in Review

Opaleye Management increased its UroGen Pharma (URGN) stake by 0.7% in Q2 2026, buying an estimated $271K and bringing the position to 1,439,996 shares worth $53M. The position accounts for 4.8% of the portfolio, ranked #5.

Opaleye Management first reported a position in URGN in Q2 2022 and has held it in 14 quarters since. 190 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Opaleye Management held 1,439,996 shares of UroGen Pharma worth $53M as of Q2 2026.
Opaleye Management bought 9,996 UroGen Pharma shares in Q2 2026, an estimated $271K.
UroGen Pharma made up 4.8% of Opaleye Management's portfolio in Q2 2026, its #5 holding.
Opaleye Management first reported a position in UroGen Pharma in Q2 2022 and has held it in 14 quarters since.
190 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Opaleye Management's 13F filing for Q2 2026, filed 14 Aug 2026.